Umckalor

Quick links to important sections

Umckalor

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Umckalor

Property Description
Active Ingredient Pelargonium sidoides root extract (standardized E.P.S. 7630)
Form Oral solution (drops)
Pharmacological Class Phytotherapeutic agent (Antimicrobial and Immunomodulatory)
Common Purpose Supportive relief for respiratory tract infections
Origin African Geranium (Pelargonium sidoides) roots

Identity and Pharmaceutical Classification of Umckalor

Umckalor is fundamentally defined as a specialized phytotherapeutic agent, meaning it is a medicine derived entirely from natural plant material. Its development and widespread use originated in Germany, and it is widely recognized across European markets. The singular active component is the liquid extract obtained from the roots of the African geranium, Pelargonium sidoides. This medicine is characterized as a monopreparation that utilizes a single active ingredient, placing it in the category of herbal medicines used for supportive respiratory therapy. It is classified as a traditional herbal medicinal product for the relief of symptoms of the common cold. This confirms the medicine's role in helping to manage the typical discomforts associated with minor respiratory infections.

Core Composition and Dosage Form

The core ingredient in Umckalor is a standardized preparation of Extractum Pelargonii sidoidis, specifically known by its proprietary designation, E.P.S. 7630. This specific extract is prepared using an aqueous-ethanolic solution, which ensures a controlled concentration of the plant's active compounds. This high degree of standardization is clinically recognized as a key factor that distinguishes the product from general, non-standardized herbal supplements. The final pharmaceutical form is an oral solution (drops), which is intended for oral administration. Studies have indicated that the extract demonstrates properties that contribute to both immunomodulatory and microbial control effects against respiratory pathogens, supporting a multi-target approach to infection. This suggests the extract provides multi-faceted support to the body's natural defense and clearance mechanisms.

General Therapeutic Purpose and Action

The general purpose of the Pelargonium sidoides root extract in Umckalor is to provide multimodal support to the patient's system during the course of minor, self-limiting upper respiratory tract infections. This function is achieved by leveraging the extract's multi-faceted action: helping to stimulate the body's natural defense mechanisms and assisting in the clearance of mucus from the airways. The liquid oral solution is specifically positioned for use across both adults and children (where appropriate) for supportive care against conditions such as the common cold and acute bronchitis.

Regulatory References

  1. European Medicines Agency

What side effects are possible with Umckalor?

Possible Side Effects and Safety Information

The safety profile for Umckalor (Pelargonium sidoides root extract, E.P.S. 7630) is officially classified based on the incidence of documented adverse reactions, adhering to standard regulatory frequency categories.

Frequency-Classified Adverse Reactions

The majority of documented reactions are classified as uncommon, affecting the gastrointestinal system, while more serious events are considered rare or very rare.

The system-organ classes involved include:

Classification System-Organ Class Examples of Documented Reactions
Uncommon Gastrointestinal disorders Stomach pain, nausea, heartburn, diarrhea
Rare Immune System Disorders, Skin and Subcutaneous Tissue Disorders, Blood and Lymphatic System Disorders Hypersensitivity (e.g., rash, pruritus, urticaria), mild gum bleeding, mild nosebleeds
Very Rare Hepatobiliary disorders Increase in liver enzyme values, jaundice

Serious Safety Considerations

The regulatory safety profile includes documentation of the potential for serious adverse reactions classified as very rare, primarily related to the hepatobiliary system. These include reports of severe liver damage, specifically cases of hepatitis and liver failure, which are subject to ongoing official safety monitoring.

Safety Restrictions and Limitations

Official labeling defines specific high-level limitations where the medicine should not be used. These safety restrictions apply to individuals with severe hepatic impairment (severe liver dysfunction) and severe renal impairment (severe kidney dysfunction). Additionally, the medicine is subject to safety restrictions in patients with a known increased bleeding tendency, a consideration arising from the documented risk of rare, minor bleeding events. These formal restrictions structure the official safety understanding of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Umckalor (Pelargonium sidoides extract) generally reflects a focus on procedural safety rather than a detailed acute toxicity profile. Currently, no specific, acute symptoms of overdose are commonly described or formally documented in the official overdose sections of major government regulatory sources for this herbal extract.

Management of a suspected overdose is therefore universally addressed through standardized emergency protocol.


Immediate Actions

Action Rationale (Label-Derived)
Seek medical help immediately or contact a Poison Control Center. This instruction is a mandatory consumer safety directive to ensure proper professional medical assessment of over-exposure.
Do NOT use this information to treat a suspected overdose. Only a healthcare professional can determine the necessity of intervention and proper management.

Official Overdose Statements

  • No specific toxic dose is defined in official labeling, and the overdose statement applies to any ingestion exceeding the labeled instructions.
  • The primary regulatory instruction is to contact a healthcare provider or emergency services right away following a suspected overdose.

The regulatory profile for this medication relies on the universally required instruction to seek emergency services immediately, compensating for the lack of detailed specific toxicological data in its brief overdose sections.

Therapeutic Uses of Umckalor

Umckalor is a medicinal product based on Pelargonium sidoides root extract, intended for the symptomatic management of common acute conditions affecting the upper respiratory tract. It is typically considered to alleviate discomfort associated with infections where symptoms are mild and uncomplicated. This often includes relief from manifestations of the common cold and acute bronchitis in adults and adolescents.

Key areas of use focus on mitigating symptoms such as sore throat, cough, and associated respiratory distress. The medicine is commonly utilized to support the body during the initial phase of these infections. The therapeutic application is centered on symptom reduction. This focus helps the patient maintain daily function while the body resolves the infection.

Quick Fact: Relief for Acute Bronchitis Symptoms (Umckalor is traditionally used to contribute to the soothing of cough and expectoration associated with acute bronchitis.)

Eligibility and Restrictions for Use

Official Population Eligibility Status

Eligible and Restricted Age Groups

Umckalor is formally permitted for use in adults, the elderly, and adolescents over 12 years of age. Use is also allowed for children from 6 to 12 years of age. However, official regulatory documents state that use is not recommended in children under 6 years because there is a lack of sufficient data establishing safety and efficacy in this youngest age bracket.

Absolute Contraindications

The medicine is strictly contraindicated in patients with a known history of hypersensitivity to the Pelargonium sidoides root extract or any other component in the specific formulation. Furthermore, use is restricted and generally contraindicated in individuals with pre-existing severe liver diseases or severe kidney diseases.

Pregnancy and Other Limitations

Based on regulatory assessment, the use of Umckalor is not recommended during either pregnancy or lactation. This restriction is due to the absence of sufficient data to establish safety for the mother and child in these specific populations. Patients with an increased tendency to bleeding are also advised against use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Umckalor (Pelargonium sidoides root extract) as derived from government regulatory documentation.


Formal Contraindicated Combinations and Pharmacodynamic Risk

Anticoagulants and Antiplatelet Drugs: Co-administration with blood-thinning medications, such as warfarin, is formally contraindicated in patients with an increased tendency to bleeding. This restriction is based on the theoretical risk of an additive pharmacodynamic effect that could increase the risk of bleeding.

Immunosuppressants: A precautionary interaction is noted with immunosuppressive drugs. Due to the extract’s established immunomodulatory activity, there is a theoretical concern that it could potentially decrease the intended therapeutic effect of the co-administered immunosuppressive medicine.


Absence of Documented Pharmacokinetic or Ingestive Interactions

Metabolic and Clearance Effects: Regulatory documents do not formally document any clinically significant pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, that would alter the systemic exposure of other medicines.

Food, Alcohol, and Timing: Official regulatory labeling explicitly states that there are no known concerns regarding co-administration with food or alcohol. Furthermore, no mandatory timing separation rules for administration relative to other medicinal products are documented in the official prescribing information.

Mechanism of Action

Umckalor, an extract of Pelargonium sidoides roots, contains distinct coumarin and phenolic acid derivatives that mediate its physiological effects. The primary mechanism involves the modulation of cellular immune response. Components interact with phagocytic cells, such as macrophages and neutrophils, enhancing the release of specific cytokines and chemokines. This interaction increases the cellular machinery's capacity to recognize and process certain microbial components at the site of accumulation.

Simultaneously, the extract exerts effects on the mucociliary system within the respiratory tract. Certain molecules decrease the adherence of microbial organisms to respiratory epithelial cell surfaces. Concurrently, other constituents may increase the ciliary beat frequency and modify the viscoelastic properties of respiratory mucus. Collectively, these actions facilitate the physical clearance of particulate matter and microorganisms from the airways, a process known as mucociliary transport.

Dosage and Administration Information

Official Administration Guidelines for Umckalor (E.P.S. 7630)

Umckalor, containing the Pelargonium sidoides root liquid extract (E.P.S. 7630), is designed exclusively for oral use in the form of drops or tablets. The standard usage protocol outlines specific dosing magnitudes, frequency, and administration conditions to ensure consistent application of the phytotherapeutic agent.


Dosing and Administration Schedule

Administration for the liquid extract (drops) is prescribed three times daily (t.i.d.) in the morning, midday, and evening. The drops must be diluted with a small amount of water prior to ingestion and are typically taken approximately half an hour before meals.

Age Group Single Dose (Drops) Daily Frequency
Adults and Adolescents (12+ years) 30 drops 3 times daily
Children 6–12 Years 20 drops 3 times daily

Course Duration and Procedural Rules

The total duration of use for symptom relief is generally intended to be short-term. Official guidelines suggest that treatment should ideally continue for several days after symptoms subside to minimize the chance of relapse, though the overall course should not exceed one week without medical consultation. If a dose is missed, it should be taken as soon as remembered, but a double dose must be avoided if the next scheduled dose is near. Use in children under 6 years of age is not established in official product labeling. This framework dictates a consistent procedural sequence, ensuring the liquid extract is taken under specific conditions and for a defined duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the structure of the available clinical research, summarizing what has been studied, the patterns reported in trials, and what still remains uncertain, without providing any individual medical advice.


Research Evidence / Overview of Studies for Chronic Insomnia

Chronic insomnia was studied for outcomes related to sleep, a condition characterized by fluctuating or episodic manifestations of difficulty falling or staying asleep. These studies have primarily consisted of short-term randomized controlled trials (RCTs). Research examined outcomes related to systemic or functional imbalance, including measurements of objective and patient-reported sleep parameters.

Studies monitored how symptoms evolved in the observed adult populations over defined, typically short, time intervals. Studies report how measured sleep parameters evolved in the observed populations, and data show patterns related to symptom intensity or variability. Research highlights changes measured during the study period, but certainty remains low and evidence is limited, reflecting the short duration of these initial trials.

Research Evidence / Overview of Studies for Primary Restless Legs Syndrome (RLS)

Research has explored primary Restless Legs Syndrome (RLS), a condition where symptoms may vary in intensity and present with cycles of stability and flare-ups. Research examined the use through short-to-medium-term RCTs and some observational settings evaluating daily-life functioning. The studies explored outcomes related to physical discomfort by measuring changes in RLS symptom severity and also monitored outcomes reflecting daily functioning or activity level.

Studies report how symptoms evolved in the observed populations with RLS over defined time intervals. Data show patterns related to the monitored symptom severity scores. Research describes short-term symptom changes, with data showing patterns related to patient-reported experiences.

What is Still Uncertain About the Research

The body of research has several limitations. Comparative evidence is lacking, and evidence quality varies across studies. Findings were mixed in some areas, and certainty remains low. Sample sizes were modest in many trials, which means research does not determine whether an individual will respond similarly to the patterns observed in group data. Additionally, follow-up durations were limited, and there is limited information regarding the long-term outcomes and the persistence of effects across the studied conditions. Limited data also exist for specific demographics like children and the elderly.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Chronic insomnia (NG225)
  2. ACR/ARP White Paper on Fibromyalgia: A Call to Action

Frequently Asked Questions (FAQ)

Common questions about Umckalor (FAQ)

Q: What is Umckalor and what is it used for?

A: Umckalor is a commercially available preparation containing a liquid extract from the roots of Pelargonium sidoides. It has been traditionally researched for conditions affecting the respiratory system, such as the common cold. It is important to consult a healthcare professional regarding its appropriate use.

Q: How does Umckalor work?

A: Research suggests that the chemical components within Pelargonium sidoides extract may affect certain markers in the body associated with immune response or the ability of some bacteria to adhere to cells. However, the precise way it exerts any observed effects is still under investigation, and its mechanism is not fully established.

Q: What evidence is available regarding its effectiveness for the common cold?

A: Several clinical studies have investigated the use of Pelargonium sidoides extract for respiratory tract infections, including the common cold. Some of these studies suggest an association with symptom duration or severity. However, the quality and consistency of the evidence vary, and it is not considered a proven therapeutic agent. Evidence is limited and ongoing research is necessary to confirm any potential benefit.

Q: Can Umckalor be taken with other medications?

A: Before combining Umckalor with any prescription or over-the-counter medications, including blood thinners, consult with a pharmacist or healthcare provider. They can assess potential interactions based on your specific health profile and current treatments.

Q: Are there any known side effects or safety concerns with Umckalor?

A: As with any product, individuals may experience side effects. Adverse events reported in clinical trials have generally been minor and may include gastrointestinal upset, bleeding of the gums or nose, or skin reactions. If you experience any severe or concerning reactions, seek immediate medical attention.

How should Umckalor be stored and disposed of?

Official Storage and Disposal Requirements

Umckalor (Pelargonium sidoides root extract oral solution) must be stored and disposed of according to regulations to maintain product stability and ensure public safety.

Storage Conditions

Requirement Official Rule
Temperature Store below 25°C. Do not refrigerate or freeze.
Protection Store in the original container and outer carton to protect from light. Keep the container tightly closed.
Stability The medicine has an in-use shelf life (e.g., 6 months) after the first bottle opening.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Umckalor must be disposed of according to local requirements defined in the regulatory labeling. The product must not be discarded with ordinary household waste or poured into wastewater. Patients are typically instructed to return unused medicine to a pharmacy or a designated collection point for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Umckalor found in:

A-Z Index: